Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12618001957280
Ethics application status
Approved
Date submitted
20/11/2018
Date registered
4/12/2018
Date last updated
20/03/2019
Date data sharing statement initially provided
4/12/2018
Type of registration
Prospectively registered

Titles & IDs
Public title
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GS-4224 in Healthy Volunteers and Subjects with the Chronic Hepatitis B (CHB) Virus
Scientific title
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GS-4224 in Healthy Volunteers and Subjects with the Chronic Hepatitis B (CHB) Virus
Secondary ID [1] 296603 0
GS-US-439-4660
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hepatitis B 310412 0
Condition category
Condition code
Infection 309125 309125 0 0
Other infectious diseases
Oral and Gastrointestinal 309126 309126 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
This is a Phase 1, placebo-controlled, randomized study evaluating the safety, PK, and PD of GS-4224. The study will consist of 2 parts (A and B).

Part A: Up to 149 subjects
Cohorts 1-7: Up to 105 subjects (12 active, 3 placebo per cohort)
Single and Multiple Ascending Doses (S/MAD):
Randomized, blinded, placebo-controlled, single- and multiple-doses with staggered GS-4224 dose escalations.
For cohorts 2-10, the dose of GS-4224 will be determined following the review of safety data from previous cohort.

Cohort 1: GS-4224 20 mg (2 x 10 mg tablets) will be administered orally in a single dose and once daily for 10 days
Cohort 2: GS-4224 up to 60 mg will be administered orally in a single dose and once daily for 10 days
Cohort 3: GS-4224 up to 180 mg will be administered orally in a single dose and once daily for 10 days
Cohort 4: GS-4224 up to 540 mg will be administered orally in a single dose and once daily for 10 days
Cohorts 5-7: GS-4224 up to 1000 mg will be administered orally in a single dose and once daily for 10 days

Cohort 8: Up to 20 subjects, for 17 evaluable
GS-4224 and tenofovir alafenamide (TAF) Drug-Drug Interaction (DDI):
Open label, two treatment, fixed sequence, DDI with single-dose TAF and multiple-doses GS-4224.

Cohort 8: GS-4224 up to 1000 mg will be administered orally once daily for 10 days, with TAF (1 x 25 mg) administered orally as a single dose on the 10th day with GS-4224 administration

Cohort 9: Up to 12 subjects, for 10 evaluable
Food Effect (FE):
Open label, two treatment, fixed sequence, single GS-4224 dose food effect evaluation.

Cohort 9: GS-4224 up to 1000 mg will be administered orally as a single dose, with a high fat/high calorie breakfast. The meal will be initiated 30mins prior to the planned study drug administration. GS-4224 will be given at or within 5 minutes of subjects consuming the meal.

Cohort 10: Up to 12 subjects, for 10 evaluable
Acid Reducing Agent Effect (ARA):
Open label, three treatment, fixed sequence, DDI with single dose GS 4224 and single doses of famotidine (FAM).

Cohort 10: GS-4224 up to 1000 mg will be administered orally as a single dose, 2 hrs after FAM (1 x 40 mg) administered orally as a single dose, and 12 hrs after FAM (1 x 40 mg) administered orally as a single dose

Part B: Approximately 60 subjects
Multicenter, randomized, blinded, placebo-controlled study of GS 4224 in subjects with CHB.

Cohorts 11-16: Approximately 10 subjects (GS-4224: n=8 and PTM: n= 2) in each cohort

Cohort 11-16: GS-4224 up to the highest dose (mg) deemed safe from Part A will be administered orally for 28 daily doses

Dosing is planned in up to 6 cohorts as described below:
Adaptive Cohorts 11-13 in virally suppressed CHB subjects:
Randomized, blinded, placebo-controlled, multiple (28) daily doses of a dose at or below the highest dose (mg) deemed safe from Part A, Cohorts 1-7 of GS-4224 or Placebo to Match (PTM) administered daily. Cohorts 11 through 13 may be conducted in parallel, staggered or sequential fashion. If conducted in a staggered manner, dose escalation between Cohorts 11-13 will take place after review of the safety data up to Day 14 and available PK and PD data.

Adaptive Cohort 14 in viremic CHB subjects not on OAV treatment:
Randomized, blinded, placebo-controlled, multiple (28) daily doses of a dose at or below the highest dose (mg) deemed safe from Part A, Cohorts 1-7 of GS-4224 or PTM administered daily. Dosing in Cohort 14 may occur after review of all available safety data up to Day 14 and available PK and PD data from Cohorts 11-13 and/or Cohorts 15-16 (if enrolled prior to commencement of Cohort 14).

Randomized, blinded, placebo-controlled, multiple (28) daily doses of a dose at or below the highest dose (mg) deemed safe from Part A, Cohorts 1-7 of GS-4224 or PTM administered daily. Dosing in Cohorts 15 and/or 16 may be conducted in parallel, staggered, or sequential fashion, but will take place after review of the safety data and available PK and PD data up to Day 14 of the respective corresponding populations from Cohorts 11-14 (e.g. if Adaptive Cohort 15 is evaluated in virally suppressed CHB subjects then only safety data from Cohorts 11-13 are required to be reviewed prior to initiation).

All doses being evaluated will be determined based on the safety and available PK and PD data from Part A, Cohorts 1-7 of this protocol and available data from the previous cohort(s) in Part B. Maximum doses evaluated in Part B will be a dose at or below the highest dose deemed to be safe in Part A, Cohorts 1-7.

The Sponsor may elect to terminate enrollment of a cohort or not to enroll a particular cohort.

The investigator will maintain an accurate inventory of all study drug(s). Each dose of the study drug(s) administered at the study centre will be administered by qualified study centre staff. The dose of study drug(s) administered to subjects in the clinic under the supervision of staff will be accurately recorded, which indicates the date and quantity of each dosage formulation dispensed to individual subjects.

Used and unused study drug supplies, including empty containers, are to be returned to the shipping facility from which it came for destruction following drug accountability and drug inventory reconciliation.
Intervention code [1] 312912 0
Treatment: Drugs
Comparator / control treatment
Placebo controlled. Each placebo tablet contains the following inactive ingredients: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, iron oxide yellow, iron oxide red, and ferrosoferric oxide
Control group
Placebo

Outcomes
Primary outcome [1] 308106 0
Part A; To evaluate the safety and tolerability of escalating single and multiple doses of GS-4224. There is no previous human experience with GS-4224 to determine possible/known adverse events. AEs will be assessed via participant reports as well as the following study assessments: physical examination, vital signs, laboratory tests (blood and urine), and 12-lead ECG.
Timepoint [1] 308106 0
The incidence of AEs and laboratory abnormalities, 12-lead ECG abnormalities, and vital signs measurements throughout the duration of the study
Primary outcome [2] 308107 0
Part A: To evaluate the PK of escalating single and multiple doses of GS-4224
Timepoint [2] 308107 0
Plasma PK parameters (eg, Cmax and AUC) of GS-4224 following intensive PK sampling.

PK assessments will be performed at the following timepoints:

Cohorts 1-7:
Days 1 and 20: 0 (pre-dose, =< 5 min before dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 18, 24, 36, 48, 72, 96 and 120 hours post dose
A pre-dose trough sample will be collected on Days 17, 18, and 19. Plasma concentrations of GS-4224 (and metabolites, if appropriate) will be determined and PK parameters will be estimated.

Cohort 8:
Days 1 and 17 (TAF): 0 (pre-dose, =< 5 min before dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 18, 24, 36, 48, 72, and 96 hours post dose
Plasma concentrations of TAF and TFV will be determined and PK parameters will be estimated.

Cohort 9:
Days 1 and 11: 0 (pre-dose, =< 5 min before dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 18, 24, 36, 48, 72, 96 and 120 hours post dose

Cohort 10:
Days 1, 11 and 21: 0 (pre-dose, =< 5 min before dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 18, 24, 36, 48, 72, 96 and 120 hours post dose
Plasma concentrations of GS-4224 (and metabolites, if appropriate) will be determined and PK parameters will be estimated.
Primary outcome [3] 308108 0
Part B: To evaluate the safety and tolerability of multiple oral doses of GS-4224 in CHB subjects virally suppressed on OAV or viremic subjects not on OAV treatment.
This is a composite primary endpoint.
There is no previous human experience with GS-4224 to determine possible/known adverse events. AEs will be assessed via participant reports as well as the following study assessments: physical examination, vital signs, laboratory tests (blood and urine), and 12-lead ECG.
Timepoint [3] 308108 0
The primary safety endpoint of this study will evaluate the incidence of AEs and laboratory abnormalities, 12-lead ECG abnormalities and vital signs measurements of GS-4224 in CHB subjects virally suppressed on OAV or viremic not on OAV treatment
Secondary outcome [1] 353974 0
Part A: To evaluate the effect of GS-4224 on the PK of TAF and metabolite (TFV).
This a composite secondary outcome.
The outcome will be assessed by serum assay,
Timepoint [1] 353974 0
PK parameters (eg, Cmax and AUC) of TAF and TFV following intensive PK sampling.

Cohort 8: Days 1 and 17 (TAF): 0 (pre-dose, =< 5 min before dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 18, 24, 36, 48, 72, and 96 hours post dose
Plasma concentrations of TAF and TFV will be determined and PK parameters will be estimated.
Secondary outcome [2] 353975 0
Part A: To evaluate the effect of food on GS-4224 PK.
The outcome will be assessed by serum assay.
PK parameters examined are: AUClast, AUCinf, %AUCexp, Cmax, Tmax, Clast, Tlast, Lambda z, CL/F, Vz/F, and t1/2
Timepoint [2] 353975 0
PK parameters of GS-4224 in fasting and fed state and with and without an ARA following intensive PK sampling.

Cohort 9: Days 1 and 11: 0 (pre-dose, =< 5 min before dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 18, 24, 36, 48, 72, 96 and 120 hours post dose
Plasma concentrations of GS-4224 (and metabolites, if appropriate) will be determined and PK parameters will be estimated.
Secondary outcome [3] 353976 0
Part B: To characterize the PK of GS-4224 in CHB subjects virally suppressed on OAV or viremic subjects not on OAV treatment.
This a composite secondary outcome.
Timepoint [3] 353976 0
Plasma PK parameters (eg, Cmax and AUC) of GS 4224 in CHB subjects virally suppressed on OAV or viremic not on OAV treatment.

PK timepoints: Days 1 and 28: 0 (pre-dose, =< 5 min before dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 18, 24, 36, 48, 72, 96 and 120 hours post dose

Eligibility
Key inclusion criteria
Part A:
1) Have the ability to understand and sign a written informed consent form (ICF), which must be obtained prior to initiation of study procedures
2) Be aged 18 through 45 years of age, inclusive at screening
3) Be a non-smoker. The use of nicotine or nicotine-containing products must be discontinued 90 days prior to the first dose of study drug
4) Have a calculated BMI of >=19 and =< 30 kg/m2 at screening
5) Have a creatinine clearance (CLcr) >= 90 mL/min (using the Cockcroft-Gault method based on serum creatinine and actual body weight as measured at screening
6) Females of childbearing potential must have a negative serum pregnancy test at screening and negative urine pregnancy test at clinic admission (unless permanently sterile or greater than 2 years postmenopausal)
7) Male subjects and female subjects of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception.
8) Male subjects must refrain from sperm donation from clinic admission (eg, Day -2 or Day -1), throughout the study period, and continuing for at least 90 days following the last dose of study drug
9) Female subjects must refrain from egg donation and in vitro fertilization during treatment and until at least 30 days after the end of relevant systemic exposure
10) Subjects have not donated blood within 56 days of study entry or plasma within 7 days of study entry and must refrain from blood donation from clinic admission, throughout the study period, and continuing for at least 30 days following the last dose of study drug.
11) Screening laboratory and 12-lead electrocardiogram (ECG) evaluations must be without clinically significant abnormalities as assessed by the investigator
12) Have no liver disease or liver function tests such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, and total bilirubin below the upper limit of normal at screening
13) Must be willing and able to comply with all study requirements
14) Must, in the opinion of the investigator, be in good health based upon medical history and physical examination, including vital signs.

Part B:
1) Must have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
2) Adult male and non-pregnant, non-lactating female subjects, 18 - 65 years of age inclusive based on the date of the Screening visit
3) A negative serum pregnancy test is required for female subjects (unless permanently sterile or greater than two years postmenopausal)
4) Male subjects and female subjects of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception.
5) Documented evidence of chronic HBV infection (e.g. HBsAg positive for more than 6 months) with detectable HBsAg levels at Screening (no retest permitted if initial screening HBsAg is negative)
6) HBV DNA levels by central lab at Screening:
a) < 20 IU/mL (for subjects in Cohorts 11–13 and if virally suppressed subjects are enrolled into Cohorts 15 and/or 16)
b) >= 2000 IU/mL (for subjects in Cohort 14 and if subjects not on OAV therapy are enrolled into Cohorts 15 and/or 16)
7) Screening ECG without clinically significant abnormalities and with QTcF interval (QT corrected using Fridericia’s formula) =< 450 msec for males and =< 470 msec for females.
8) BMI 18-34 kg/m2 (inclusive)
9) Must be willing and able to comply with all study requirements

Additionally, subjects in Cohorts 11–13 and IF virally suppressed subjects are selected for Cohorts 15 and/or 16 should meet the following criteria to be eligible to participate in this study:

10) Have been on prescribed OAV treatment(s) (TAF, TDF and approved generics of TDF, entecavir, adefovir, lamivudine, TBV, either as single agents or in combination) with no change in regimen for 3 months prior to screening.
- TAF and TDF (or generics of TDF) are not permitted unless new data becomes available that would allow concomitant use of TAF or TDF (or generics of TDF) during the trial (Cohort 8)
11) HBV DNA < 69IU/mL measure at least once at local lab for 6 or more months prior to screening
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
Part A:
1) Be a lactating female
2) Have received any study drug within 30 days prior to study dosing
3) Have current alcohol or substance abuse judged by the investigator to potentially interfere with subject compliance or subject safety
4) Have a positive test result for HIV, HBsAg, or HCV antibody
a) Subjects who are HCV Ab positive, but have a documented negative HCV RNA, are eligible
5) Have a positive test result for autoantibodies (ANA >1:80 and/or anti-SMA >1:80 and/or AMA>1:40 and/or anti-TPO >1:40)
6) Have poor venous access that limits phlebotomy
7) Have taken any prescription medications or over-the-counter medications, including herbal products, within 28 days prior to start of study drug dosing, with the exception of vitamins and/or acetaminophen and/or ibuprofen and/or hormonal contraceptive medications.
8) Have been treated with systemic steroids, immunosuppressant therapies, or chemotherapeutic agents within 3 months prior to screening or is expected to receive these agents during the study (eg, corticosteroids, immunoglobulins, and other immune- or cytokine-based therapies)
9) Have a history of any of the following:
a) Significant serious skin disease, such as but not limited to rash, food allergy, eczema, psoriasis, or uticaria
b) Significant drug sensitivity or drug allergy (such as anaphylaxis or hepatoxicity)
c) Known hypersensitivity to the study drugs their metabolites or to formulation excipients
d) Significant cardiac disease (including history of myocardial infarction based on ECG and/or clinical history, any history of ventricular tachycardia, congestive heart failure, or dilated cardiomyopathy with left ventricular ejection fraction < 40%), a family history of long QT syndrome, or unexplained death in an otherwise healthy individual between the ages of 1 and 30 years
e) Syncope, palpitations, or unexplained dizziness
f) Implanted defibrillator or pacemaker
g) Liver disease, including Gilbert disease
h) Severe peptic ulcer disease, gastroesophageal reflux disease, or other gastric acid hypersecretory conditions requiring prolonged (> 6 months) medical treatment.
i) Medical or surgical treatment that permanently altered gastric absorption (eg, gastric or intestinal surgery). A history of cholecystectomy is not exclusionary.
10) Have any serious or active medical or psychiatric illness (including depression) that, in the opinion of the investigator, would interfere with subject treatment, assessment, or compliance with the protocol. This would include renal, cardiac, hematological, hepatic, pulmonary (including chronic asthma), endocrine (including diabetes), central nervous, gastrointestinal (including an ulcer), vascular, metabolic (thyroid disorders, adrenal disease), autoimmune disorders, immunodeficiency disorders, active infection, or malignancy that are clinically significant or requiring treatment.
11) Have received inactivated vaccinations (e.g. injectable influenza or pneumococcal) within 4 weeks prior to randomization or received live vaccinations within 4 weeks prior to screening

Part B:
1) Extensive bridging fibrosis or cirrhosis as defined clinically, by imaging or by the following:
a) Metavir >= 3 or Ishak fibrosis score >= 4 by a liver biopsy within 5 years of screening, or, in the absence of an appropriate liver biopsy, either:
b) Screening FibroTest score of > 0.48 and APRI > 0.8, or
c) Historic FibroScan with a result > 8 kPa within = 6 months of screening (if available)
If liver biopsy is available, the liver biopsy result supersedes (b) and/or (c, if available)
If an appropriate liver biopsy is not available, fibrosis will be evaluated by (b) and/or (c, if available). In the event of discordance between (b) and (c), the FibroScan results will take precedence
2) Subjects meeting any of the following laboratory parameters at screening:
a) Hemoglobin < 12 g/dL (for males) or < 11 g/dL (for females)
b) White Blood cell count < 2500 cells/uL
c) Neutrophil count < 1500 cell/mm3 (or < 1000 cell/mm3 if considered a physiological variant in a subject of African descent).
d) ALT > 3x ULN
e) INR > ULN
f) Albumin < 3.5 g/dL
g) Direct bilirubin >1.5x ULN
h) Platelet Count < 100,000 /ml
i) ANA >= 1:80
j) anti-SMA >1:80
k) AMA >1:40
l) anti-TPO >1:40
3) Estimated creatinine clearance (CRCL) < 80 ml/min (using the Cockcroft-Gault method) based on serum creatinine and actual body weight as measured at the screening evaluation.
4) Co-infection with HIV, HCV or hepatitis D virus (HDV)
a) Subjects who are HCV or HDV positive by serology, but have a documented screening negative HCV or HDV RNA, respectively, are eligible
5) Evidence of hepatocellular carcinoma (e.g. as evidenced by recent imaging)
6) Significant cardiac disease (including history of myocardial infarction based on ECG and/or clinical history, any history of ventricular tachycardia, congestive heart failure, or dilated cardiomyopathy with left ventricular ejection fraction < 40%), a family history of long QT syndrome or unexplained death in an otherwise healthy individual between the ages of 1 and 30 years
7) Malignancy within 5 years prior to screening, with the exception of specific cancers that are cured by surgical resection (e.g. basal cell skin cancer). Subjects under evaluation for possible malignancy are not eligible.
8) Significant cardiovascular, pulmonary, or neurological disease.
9) Documented myocardial infarction or unstable/uncontrolled cardiac disease (e.g., unstable angina, congestive heart failure) within 6 months of randomization should be excluded
10) Diagnosis of autoimmune disease (e.g., systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, autoimmune hepatitis, sarcoidosis, psoriasis of greater than mild severity, autoimmune uveitis, autoimmune thyroid disease), poorly controlled diabetes mellitus, significant psychiatric illness, severe chronic obstructive pulmonary disease (COPD), malignancy (with exception of certain skin cancers), hemoglobinopathy, or are immunosuppressed
11) Chronic liver disease of a non-HBV etiology (e.g. Wilson’s disease, hemochromatosis, alpha-1-antitrypsin deficiency, cholangitis), except for non-alcoholic fatty liver disease
12) History of hepatic decompensation (e.g. ascites, encephalopathy, or variceal hemorrhage) within 5 years prior to screening
13) Received solid organ or bone marrow transplant
14) Received prolonged therapy with immunomodulators (e.g. corticosteroids) or biologics (e.g. monoclonal antibody, interferon) within 3 months of screening
15) Have received inactivated vaccinations (e.g. injectable influenza or pneumococcal) within 4 weeks prior to randomization or received live vaccinations within 4 weeks prior to screening
16) Have donated blood within 28 days of screening or plasma within 7 days of screening and must refrain from blood donation from screening, throughout the study period, and continuing for at least 30 days following the last dose of study drug
17) Use of anticoagulant therapy
18) Use of another investigational agent within 30 days of screening, unless allowed by the Sponsor
19) Current alcohol or substance abuse judged by the investigator to potentially interfere with subject compliance
20) Known hypersensitivity to study drug, metabolites or formulation excipients
21) Women who are breastfeeding or may wish to become pregnant during the course of the study
22) Female subjects unwilling to refrain from egg donation and in vitro fertilization during and until at least 30 days after the last study drug dose
23) Male subjects unwilling to refrain from sperm donation during and until at least 90 days after the last dose of study drug
24) Use of any prohibited concomitant medications
25) Believed by the Study Investigator to be inappropriate for study participation for any reason not otherwise listed.
a) Additionally, subjects in Cohort 14 and IF subjects not on OAV therapy are selected for Cohorts 15 and/or 16 who meet the following criterion are not to be enrolled in this study:
26) Received OAV treatment for HBV within 3 months of screening

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Other
Other design features
Part A: is open label
Part B: Part B will enroll up to 6 cohorts. For each cohort, approximately 10 eligible subjects will be randomized 4:1 to receive either blinded GS-4224 (n=8) or PTM (n=2). At least one HBeAg negative subject will be enrolled in the placebo group within each cohort.
Phase
Phase 1
Type of endpoint/s
Safety
Statistical methods / analysis
Safety Analysis:
Safety will be assessed during the study through the reporting of adverse events, and by clinical laboratory tests, ECGs, physical examinations, and vital sign assessments.
Safety data will be summarized by treatment within Part A and by population and treatment in Part B (according to the study drug received).

Pharmacokinetic Analysis:
Part A:
Plasma PK concentrations and parameters (eg, AUClast, AUCinf, %AUCexp, Cmax, Tmax, Clast, Tlast, ?z, CL/F, and t1/2, as applicable) will be listed and summarized for GS-4224 (and its metabolites, as applicable), TAF, and TFV by treatment. Urine concentrations and PK parameters of GS-4224 (and/or metabolites, if applicable) may also be listed and summarized using descriptive statistics by treatment.

Dose proportionality will be assessed by comparing PK parameters across cohorts 1-7 using a power model to evaluate the population mean slope based on its 90% CI. An alternative evaluation of dose proportionality will be conducted using an ANOVA on dose-normalized, log-transformed data. Dose proportionality will be evaluated using the 90% CIs around the GLSM ratios of PK parameters for each dose level in comparison to the reference dose.

For cohorts 8-10, an ANOVA using a mixed-effects model with treatment as a fixed effect and subject as a random effect will be fitted to the natural logarithmic transformation of PK parameters (eg AUC and Cmax, as applicable) for GS-4224 or TAF and TFV to evaluate the effect of DDI, ARA, and food. Two-sided 90% CIs will be calculated for the ratios of GLSMs between the test and reference treatments being compared.

Part B:
Plasma PK concentrations and PK parameters (eg, AUClast, AUCinf, %AUCexp, Cmax, Tmax, Clast, Tlast, ?z, CL/F, and t1/2, as applicable) for GS-4224 (and metabolites, if applicable) will be listed and summarized using descriptive statistics by population and treatment.

Dose proportionality will be assessed by comparing PK parameters AUCtau, AUCinf, Cmax and Ctau of GS-4224 and metabolites (if applicable) across evaluated dose levels, if appropriate. Additional analysis to determine accumulation ratio may be conducted as appropriate.

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
31/01/2019
Actual
3/02/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
210
Accrual to date
17
Final
Recruitment outside Australia
Country [1] 21037 0
New Zealand
State/province [1] 21037 0

Funding & Sponsors
Funding source category [1] 301182 0
Commercial sector/Industry
Name [1] 301182 0
Gilead Sciences, Inc
Country [1] 301182 0
United States of America
Primary sponsor type
Commercial sector/Industry
Name
Gilead Sciences, Inc
Address
333 Lakeside Drive,
Foster City CA 94404
Country
United States of America
Secondary sponsor category [1] 300802 0
None
Name [1] 300802 0
Address [1] 300802 0
Country [1] 300802 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 301922 0
Health and Disability Ethics Committee (HDEC), NZ
Ethics committee address [1] 301922 0
Ethics committee country [1] 301922 0
New Zealand
Date submitted for ethics approval [1] 301922 0
22/11/2018
Approval date [1] 301922 0
11/01/2019
Ethics approval number [1] 301922 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 88570 0
Prof Edward Gane
Address 88570 0
Auckland Clinical Studies Limited
3 Ferncroft Street, Auckland 1042
Country 88570 0
New Zealand
Phone 88570 0
+64 9 373 3474
Fax 88570 0
Email 88570 0
[email protected]
Contact person for public queries
Name 88571 0
Wayne Paul
Address 88571 0
Gilead Sciences Pty Ltd
Level 6, 417 St Kilda Road
Melbourne VIC 3004
Country 88571 0
Australia
Phone 88571 0
+61 3 9272 4451
Fax 88571 0
Email 88571 0
[email protected]
Contact person for scientific queries
Name 88572 0
Audrey Lau
Address 88572 0
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404
Country 88572 0
United States of America
Phone 88572 0
+1650 4255065
Fax 88572 0
Email 88572 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Undecided
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.